Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | GPR18 | Q14330 | 9/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20557527 | 0.80 | GBA1 (0.51) | CCNE2CCNE1CDK2GPR18KMT2A | |
| SCHEMBL20267087 | 0.78 | KMT2A (0.67) | KMT2APOLBSLC2A1RAD52LMNA | |
| SCHEMBL2358849 | 0.76 | CDK2 (0.58) | CCNE2CCNE1CDK2GPR18CNR1 | |
| SCHEMBL21758302 | 0.75 | USP2 (0.44) | GPR18CNR1CNR2KMT2APOLB | |
| SCHEMBL2317916 | 0.75 | CYP2D6 (0.47) | RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL29244533 | 0.74 | KMT2A (0.54) | CDK2KMT2APOLBSLC2A1RAD52 | |
| SCHEMBL21754307 | 0.74 | KMT2A (0.51) | KMT2APOLBSLC2A1RAD52NPC1 | |
| SCHEMBL30278019 | 0.74 | HTR2A (0.52) | CDK2KMT2APOLBSLC2A1RAD52 | |
| SCHEMBL27253699 | 0.74 | HTR2A (0.52) | CDK2KMT2APOLBSLC2A1RAD52 | |
| SCHEMBL27846131 | 0.74 | CDK2 (0.49) | CCNE2CCNE1CDK2GPR18CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3612030-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Kyn Therapeutics (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110831600-A | Indole AHR inhibitors and uses thereof | 金恩医疗公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20180327411-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| WO-2018195397-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | KYN THERAPEUTICS (US) | 2018-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327411-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CCNE2 3358/4885CCNE1 4009/4885CDK2 1444/4885 |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CCNE2 3358/4885CCNE1 4009/4885CDK2 1444/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CCNE2 3358/4885CCNE1 4009/4885CDK2 1444/4885 |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CCNE2 3358/4885CCNE1 4009/4885CDK2 1444/4885 |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CCNE2 3358/4885CCNE1 4009/4885CDK2 1444/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CCNE2 3358/4885CCNE1 4009/4885CDK2 1444/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CCNE2 3358/4885CCNE1 4009/4885CDK2 1444/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CCNE2 3358/4885CCNE1 4009/4885CDK2 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.